Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA9 | Q16790 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | CA4 | P22748 | 2/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.64 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.64 |
| ▸ | CA6 | P23280 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4652941 | 0.82 | ALDH1A1 (0.56) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL27817575 | 0.81 | ALDH1A1 (0.95) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL28304078 | 0.81 | KDM4E (0.61) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL5183939 | 0.81 | ALDH1A1 (0.95) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL28438953 | 0.81 | ALDH1A1 (0.95) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| Salicylic Acid SCHEMBL971594 | 0.81 | ALDH1A1 (0.95) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| 2,2'-Dihydroxybenzphenone SCHEMBL29572496 | 0.80 | HPGD (0.67) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL9797513 | 0.80 | KDM4E (0.67) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| 2,2'-Dihydroxybenzphenone SCHEMBL18422 | 0.80 | HPGD (0.67) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL29861559 | 0.80 | KDM4E (0.67) | KDM4EHPGDALDH1A1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117229779-A | Near-infrared cyanine dye sensitized rare earth up-conversion luminescence nano probe, preparation method and application thereof | 复旦大学 | 2023-12-15 | — | — | CN | claimed |
| WO-2020228635-A1 | EGFR KINASE INHIBITOR AND APPLICATION THEREOF IN PREPARING ANTI-CANCER DRUG | 浙江大学 | 2020-11-19 | — | — | WO | claimed |
| CN-111909101-A | EGFR kinase inhibitor and application thereof in preparation of anti-cancer drugs | 浙江大学 | 2020-11-10 | — | — | CN | claimed |
| EP-2697206-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S A (LU) | 2019-04-03 | — | — | EP | claimed |
| WO-2008012603-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF DIFLUNISAL AND RELATED COMPOUNDS WITH VERY FAST SKIN PENETRATION RATE | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-31 | — | — | WO | claimed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | claimed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | claimed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | claimed |
| CN-1199396-A | Novel azepanes and their ring homologues for therapy and prophylaxis of protein kinase mediated diseases | HOFFMANN LA ROCHE (CH) | 1998-11-18 | — | — | CN | claimed |
| CN-1033153-A | The pharmaceutical preparation of estrogen-like effects | RASCHIGELINO HIMICHESKI YINSTI (SU) | 1989-05-31 | — | — | CN | claimed |
| CN-117229779-A | Near-infrared cyanine dye sensitized rare earth up-conversion luminescence nano probe, preparation method and application thereof | 复旦大学 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023127699-A1 | MODIFIED VINYL ALCOHOL POLYMER AND METHOD FOR PRODUCING SAME | 株式会社クラレ | 2023-07-06 | — | — | WO | disclosed |
| CN-111909101-B | EGFR kinase inhibitor and application thereof in preparation of anti-cancer drugs | 浙江大学 | 2022-07-19 | — | — | CN | disclosed |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2021-11-18 | — | — | US | disclosed |
| WO-2020228635-A1 | EGFR KINASE INHIBITOR AND APPLICATION THEREOF IN PREPARING ANTI-CANCER DRUG | 浙江大学 | 2020-11-19 | — | — | WO | disclosed |
| US-4644011-A | LIVER AND VIEN DISORDERS | ZYMA SA (CH) | 1987-02-17 | — | — | US | disclosed |
| EP-0096007-A2 | Pharmaceutical preparations containing (+)-cyanidan-3-ol derivatives, the use thereof, novel substituted (+)-cyanidan-3-ol derivatives, and processes for producing them | Zyma SA (CH) | 1983-12-07 | — | — | EP | disclosed |
| US-4101464-A | Process for preparing foamed solids using two or more azo compounds | PENNWALT CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4029615-A | AZO COMPOUNDS | PENNWALT CORPORATION (US) | 1977-06-14 | — | — | US | disclosed |
| US-3993609-A | ACID SENSITIVE AZO PROMOTERS | PENNWALT CORPORATION (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | KDM4E 2728/4885HPGD 441/4885ALDH1A1 525/4885 |
| US-20210353579-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | KDM4E 4795/4885HPGD 17/4885ALDH1A1 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.